Search clinical trials for: E2080

Total 8 results

Eisai Inc.

Completed

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

Epilepsy

United States
Eisai Inc.

Terminated

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Refractory Partial Onset Seizures

United States
Eisai Limited

Completed

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)

Lennox-Gastaut Syndrome

Japan
Eisai Inc.

Available

An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

Lennox Gastaut Syndrome

Poland
Eisai Co., Ltd.

Completed

A Long Term Extension Study of E2080 in Lennox-Gastaut Patients

Lennox-Gastaut Syndrome

Japan
University of South Alabama

Withdrawn

Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures

Refractory Partial Seizures

United States
Eisai Inc.

Completed

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

Lennox-Gastaut Syndrome

France, Poland, United States, South Africa, Italy, Canada, Greece
Eisai Limited

Completed

European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS)

Lennox-Gastaut Syndrome

France, United Kingdom, Germany, Spain, Denmark, Austria, Italy, Sweden

3

Subscribe